Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basmisanil in Dup15q Syndrome
NCT07846215Phase 2Not yet recruiting
- Sponsor
- Newleos Therapeutics
- Start
- Dec 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
A Phase 2 trial of basmisanil in dup15q syndrome, sponsored by Newleos Therapeutics. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
basmisanil
03
Conditions
dup15q syndrome
Beyond the preview
Go deeper on NCT07846215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07846215.